Thromboxane receptor antagonists
AssigneeUniversity College Dublin, National University of Ireland, Dublin
InventorsB. Therese Kinsella, Patrick Guiry, Helen Reid, Barry O'Connor
Life of this patent
Estimating the term…
Abstract
The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.
Claims16
A compound of formula (I):
- wherein:
- R1 is an alkyl group;
- and
- R2 is an aryl group, or a pharmaceutically acceptable salt thereof.
A compound of formula (XXII):
- wherein R10 is selected from the group consisting of
- H, NH2, I,
- and CO2Me, or a pharmaceutically acceptable salt thereof.
A compound of formula (XXII):
- wherein R10 is selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
A compound of a formula selected from the group consisting of (LVII), (LVIII), (LIX), and (LX):
- or a pharmaceutically acceptable salt thereof.
A method of treating a condition selected from the group consisting of:
- atherothrombosis, stroke, myocardial infarction, atherosclerosis, arteriosclerotic vascular disease, thromboembolism, deep vein thrombosis, arterial thrombosis, ischemia, peripheral vascular disease, peripheral artery occlusive disease, coronary artery disease, angina pectoris, and transient ischemic attack in a patient in need thereof, the method comprising administering to said patient a compound of formula (I):
- wherein:
- R1 is an alkyl group;
- and
- R2 is an aryl group, or a pharmaceutically acceptable salt thereof.
A method of treating a condition selected from the group consisting of:
- atherothrombosis, stroke, myocardial infarction, atherosclerosis, arteriosclerotic vascular disease, thromboembolism, deep vein thrombosis, arterial thrombosis, ischemia, peripheral vascular disease, peripheral artery occlusive disease, coronary artery disease, angina pectoris, and transient ischemic attack in a patient in need thereof, the method comprising administering to said patient a compound of formula (XXII):
- wherein R10 is selected from the group consisting of
- H, NH2, I,
- and CO2Me, or a pharmaceutically acceptable salt thereof.
A method of treating a condition selected from the group consisting of:
- atherothrombosis, stroke, myocardial infarction, atherosclerosis, arteriosclerotic vascular disease, thromboembolism, deep vein thrombosis, arterial thrombosis, ischemia, peripheral vascular disease, peripheral artery occlusive disease, coronary artery disease, angina pectoris, and transient ischemic attack in a patient in need thereof, the method comprising administering to said patient a compound of formula (XXII):
- wherein R10 is selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
A method of treating a condition selected from the group consisting of:
- atherothrombosis, stroke, myocardial infarction, atherosclerosis, arteriosclerotic vascular disease, thromboembolism, deep vein thrombosis, arterial thrombosis, ischemia, peripheral vascular disease, peripheral artery occlusive disease, coronary artery disease, angina pectoris, and transient ischemic attack in a patient in need thereof, the method comprising administering to said patient a compound selected from the group consisting of (LVII), (LVIII), (LIX), and (LX):
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.